Market News AIOpen the app

Johnson & Johnson has asked the FDA to approve Caplyta for treating bipolar mania.

TrialRead the original at prnewswire.com
Good for JNJ

Johnson & Johnson submitted Caplyta for bipolar mania, with 2 studies showing fewer manic symptoms than placebo by Day 3. Approval is still pending, but another adult use could add value to a drug central to its $14.6 billion purchase.

JNJ · Johnson & Johnson

AI read · Good for JNJ

The AI's read

The study results give regulators evidence to review, and another adult use could strengthen the value of a medicine central to J&J's purchase. Approval is still needed, so that benefit is not secured.

Get alerts for JNJ

Follow Johnson & Johnson (JNJ) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for JNJ
Free on the App Store and Google Play, or on the web.